Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KETOPROFEN vs ABSTRAL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.
Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Mild to moderate pain,Dysmenorrhea,Acute gouty arthritis (off-label)
Management of breakthrough pain in cancer patients aged 18 and older who are already receiving and tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain.
Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.
For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.
Terminal elimination half-life: 2-4 hours; clinical context: short half-life allows for quick drug clearance but requires frequent dosing; may be prolonged in elderly or renal impairment.
Terminal elimination half-life: 6-10 hours (mean 8 hours); prolonged in elderly and hepatic impairment
Hepatic metabolism via cytochrome P450 (CYP) enzymes, primarily CYP3A4 and CYP2C9; conjugation with glucuronic acid; minor hydrolysis to metabolites.
Hepatic metabolism primarily via CYP3A4; major metabolites include norfentanyl (inactive) and other minor metabolites.
Renal: ~80% (60% as glucuronide conjugates, 20% as unchanged drug); Biliary/Fecal: ~20% via bile.
Renal: ~70% as metabolites (primarily fentanyl conjugates and norfentanyl), ~10% unchanged; Fecal: ~9%; Biliary: minimal
99% bound, primarily to albumin; free fraction increases in hypoalbuminemia.
80-85% bound primarily to albumin and alpha-1-acid glycoprotein
0.1-0.2 L/kg; clinical meaning: low Vd indicates limited tissue distribution, primarily confined to plasma and extracellular fluid; higher in elderly due to increased body fat.
4-6 L/kg; large Vd indicates extensive tissue distribution
Oral: ~90% (capsules); Topical: 5-10% (systemic absorption); Rectal: ~80%; Intramuscular: ~100%.
Sublingual: 70-90% (mean 80%); buccal: 50-65%; oral: ~30% due to first-pass metabolism
Cr Cl >50 m L/min: no adjustment. Cr Cl 25-50 m L/min: reduce dose to 50% of normal. Cr Cl <25 m L/min: avoid use or maximum 50 mg twice daily.
No specific GFR-based dose adjustment recommended; use caution in severe renal impairment (Cr Cl <30 m L/min) due to potential accumulation of fentanyl.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
For Child-Pugh Class A or B: no adjustment required; for Child-Pugh Class C: reduce dose and monitor closely for toxicity due to reduced clearance.
Children ≥6 months: oral 1-2 mg/kg/day divided every 6-8 hours; maximum 4 mg/kg/day. Not to exceed adult maximum.
Not approved for pediatric patients <18 years; safety and efficacy not established.
Initiate at lowest effective dose (e.g., 50 mg twice daily); use short duration; monitor renal function, GI bleeding, and cardiovascular risk.
Initiate at the lowest available dose (100 mcg) and titrate cautiously; elderly patients may have altered pharmacokinetics and increased sensitivity to fentanyl.
Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors may be at greater risk. NSAIDs are contraindicated for treatment of perioperative pain in the setting of coronary artery bypass graft (CABG) surgery.
Risk of respiratory depression, addiction, abuse, and misuse; risk of accidental ingestion; risk of medication errors resulting in fatal overdose; life-threatening respiratory depression in opioid-non-tolerant patients; risk of opioid analgesic drug interactions with CNS depressants; risk of neonatal opioid withdrawal syndrome with prolonged use during pregnancy.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; congestive heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions; hematologic toxicity; hepatic toxicity; use with caution in patients with asthma or history of GI bleeding.
Respiratory depression, QT prolongation, serotonin syndrome, adrenal insufficiency, severe hypotension, seizures, biliary tract disease, gastrointestinal obstruction, withdrawal syndrome, and risk of overdose with alcohol or other CNS depressants.
History of hypersensitivity to ketoprofen, aspirin, or other NSAIDs; active peptic ulcer disease; history of gastrointestinal bleeding or perforation; severe renal impairment; severe hepatic impairment; during perioperative pain in CABG surgery.
Hypersensitivity to fentanyl or any components; opioid-non-tolerant patients; acute or severe bronchial asthma; known or suspected gastrointestinal obstruction; concurrent use of MAOIs or within 14 days of discontinuation.
Avoid alcohol as it increases the risk of GI bleeding. Taking with food may reduce gastrointestinal irritation but delays absorption.
Avoid grapefruit and grapefruit juice during treatment as they inhibit CYP3A4, increasing fentanyl exposure. No other significant food interactions; however, avoid alcohol due to additive CNS depressant effects. Maintain consistent meal timing relative to dosing to minimize variability.
First trimester: Avoid due to risk of spontaneous abortion and major congenital malformations (cardiac, gastroschisis). Second trimester: Avoid if possible; associated with oligohydramnios, constriction of ductus arteriosus. Third trimester: Contraindicated due to risk of premature closure of ductus arteriosus, oligohydramnios, fetal nephrotoxicity, and periventricular hemorrhage.
FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in animal studies. Second trimester: No specific malformation risk. Third trimester: Prolonged use can cause neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth.
Compatible with caution. Small amounts excreted in breast milk (M/P ratio ~0.01-0.1). Due to risk of infant toxicity (e.g., gastrointestinal effects, renal impairment), consider alternative analgesics. Monitor infant for drowsiness, poor feeding, or rash.
Minimal excretion into breast milk; M/P ratio not reported. Fentanyl is poorly absorbed orally, making significant infant exposure unlikely. Monitor infant for sedation, respiratory depression, and poor feeding. Avoid use in breastfeeding mothers with opioid dependence or high doses.
No specific dose adjustments recommended; use lowest effective dose for shortest duration. Increased clearance in pregnancy may necessitate dose adjustment, but avoid in third trimester. Use with caution in first and second trimesters due to maternal volume expansion and increased renal clearance.
Pregnancy increases clearance and volume of distribution, potentially reducing drug levels. Dose adjustments may be needed: initiate with lower doses and titrate to effect; consider increasing frequency or using breakthrough doses. Monitor for inadequate analgesia. Avoid abrupt discontinuation; taper if stopping.
Maximum analgesic effect occurs at 50 mg oral doses; higher doses increase GI toxicity without additional pain relief. Use with caution in patients with renal impairment as ketoprofen decreases renal blood flow. Avoid use with other NSAIDs, including aspirin, due to increased ulcer risk. Ketoprofen is highly protein-bound; monitor for displacement interactions with warfarin and oral hypoglycemics.
ABSTRAL (fentanyl sublingual spray) is a transmucosal immediate-release fentanyl (TIRF) formulation indicated for breakthrough pain in opioid-tolerant patients. Due to high bioavailability (~70%) and rapid onset (peak plasma concentration at 15-30 minutes), initial titration must start with 100 mcg, with dose escalation based on efficacy and tolerability. Weight-based conversion from other fentanyl products is not valid; utilize the provided conversion table. Patients must have a rescue agent (e.g., naloxone) available. Concomitant use with CYP3A4 inhibitors (e.g., ketoconazole, ritonavir) or inducers (e.g., rifampin, carbamazepine) requires dose adjustment. Avoid use in opioid-naïve patients due to risk of respiratory depression.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose; taking more does not provide extra pain relief.,Avoid alcohol while taking this medication.,Contact your doctor immediately if you experience black or bloody stools, chest pain, or signs of an allergic reaction.,Do not take with other NSAIDs or aspirin without consulting your healthcare provider.
Use only for breakthrough cancer pain while on around-the-clock opioid therapy.,Do not switch from other fentanyl products based on dose; follow specific conversion instructions.,Spray entire dose into mouth; do not swallow or rinse for at least 10 minutes.,Store at room temperature, away from children and pets.,Dispose of unused units via drug take-back program or by flushing down toilet per FDA guidelines.,Never share this medication with others; death may occur.,Seek emergency if severe drowsiness, confusion, or slow breathing occurs.
"The concurrent use of ketoprofen, a nonsteroidal anti-inflammatory drug (NSAID), with gemeprost, a synthetic prostaglandin E1 analogue used for cervical ripening and induction of labor, may antagonize the therapeutic effects of gemeprost. Ketoprofen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis, which directly opposes the prostaglandin-mediated actions of gemeprost, such as cervical softening and uterine contraction. This pharmacodynamic antagonism can lead to decreased efficacy of gemeprost in achieving cervical ripening or inducing labor, potentially prolonging the induction-to-delivery interval or necessitating alternative interventions."
"Amodiaquine inhibits CYP2C9, the primary enzyme responsible for metabolizing ketoprofen. This results in decreased clearance and elevated plasma concentrations of ketoprofen, increasing the risk of dose-dependent adverse effects such as gastrointestinal bleeding, renal impairment, and central nervous system toxicity. Clinically, patients may experience heightened analgesic and anti-inflammatory effects, but also a greater propensity for NSAID-related toxicity."
"Lumacaftor, a strong cytochrome P450 (CYP) 3A4 inducer, significantly decreases the systemic exposure of ketoprofen, a CYP3A4 substrate, by increasing its hepatic metabolism. This interaction can lead to reduced ketoprofen plasma concentrations, potentially compromising its analgesic and anti-inflammatory efficacy. Clinically, patients may experience suboptimal pain relief or require alternative pain management strategies."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KETOPROFEN vs ABSTRAL, answered by our medical review team.
KETOPROFEN is a NSAID that works by Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis; also inhibits leukotriene synthesis and has direct membrane-stabilizing effects.. ABSTRAL is a Opioid Analgesic that works by Fentanyl is a potent mu-opioid receptor agonist, producing analgesia and sedation by activating G-protein coupled opioid receptors in the central nervous system.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KETOPROFEN and ABSTRAL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KETOPROFEN is: Oral: 75 mg three times daily or 50 mg four times daily; maximum 300 mg/day. Intravenous: 100 mg every 12-24 hours, infused over 15-30 minutes.. The standard adult dose of ABSTRAL is: For breakthrough pain in opioid-tolerant patients: initial dose 100 mcg sublingual tablet, titrate across strengths (100, 200, 300, 400, 600, 800 mcg) as needed; maximum 2 doses per episode, minimum 2 hours between episodes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KETOPROFEN and ABSTRAL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KETOPROFEN is classified as Category D/X. First trimester: Avoid due to risk of spontaneous abortion and major congenital malformations (cardiac, gastroschisis). Second trimester: Avoid if possible; associated with oligohy. ABSTRAL is classified as Category C. FDA Pregnancy Category C. First trimester: Inadequate human data; opioid analgesics are not associated with major malformations but may cause neural tube defects at high doses in a. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.